Innovent Biologics and Pfizer have entered into a major global oncology collaboration aimed at accelerating the development of next-generation cancer therapies, with a deal potentially worth up to $10.5 billion. The agreement focuses on the research and development of 12 early-stage and de novo cancer medicines, spanning advanced antibody-drug conjugates (ADCs) and multispecific antibody therapies designed to improve treatment outcomes for cancer patients worldwide.
The strategic licensing and collaboration agreement combines Innovent’s oncology discovery and early clinical development strengths with Pfizer’s global drug development, regulatory expertise and commercial infrastructure. The partnership reflects growing industry efforts to combine scientific innovation with global commercialization capabilities to bring breakthrough cancer therapies to market more quickly.
Under the terms of the deal, the portfolio will include eight early-stage oncology programs developed by Innovent and four discovery-stage programs proposed by Pfizer. The therapies are expected to focus on promising new modalities such as ADCs with differentiated payload technologies and multispecific antibodies designed to engage the immune system in novel ways.
ADCs have become one of the pharmaceutical industry’s fastest-growing areas of oncology research, as they are engineered to deliver cancer-fighting agents directly to tumor cells while limiting damage to healthy tissue. Multispecific antibodies, meanwhile, are being explored for their ability to simultaneously target multiple disease pathways or immune system mechanisms, potentially improving treatment effectiveness in difficult-to-treat cancers.
According to the agreement, Innovent will lead development of the programs through Phase 1 clinical trials using its proprietary discovery engine and early-stage research capabilities. Following Phase 1 development, Pfizer will assume responsibility for future global development, leveraging its international clinical trial network and commercialization experience.
The collaboration establishes multiple licensing and commercialization pathways. Four programs will be jointly developed worldwide, with both companies sharing development costs, co-commercializing products in the United States and Europe, and splitting profits. Innovent will retain commercialization rights in Greater China for these therapies.
For another four programs, Pfizer will receive exclusive licensing rights outside Greater China and will bear most development costs. The remaining four programs will be exclusively licensed to Pfizer globally, with the U.S.-based drugmaker responsible for worldwide development and commercialization.
Financially, the partnership represents one of the largest oncology collaborations involving a Chinese biotechnology company. Innovent will receive an upfront payment of $650 million and may earn up to $9.85 billion in development, regulatory and commercial milestone payments. In addition, the company is eligible for double-digit royalties on approved products, while co-developed therapies marketed in the United States and Europe would generate shared profits for both firms.
Executives from both companies described the partnership as an opportunity to accelerate innovative cancer medicines for patients globally. The transaction remains subject to required regulatory approvals before closing.